rs375722926

Variant summary

Our verdict is Likely benign. The variant received -4 ACMG points: 1P and 5B. PP3BP6BS1

The NM_001039213.4(CEACAM16):​c.116T>A​(p.Leu39Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000483 in 1,613,712 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. L39L) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00023 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000029 ( 0 hom. )

Consequence

CEACAM16
NM_001039213.4 missense

Scores

6
5
8

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:1

Conservation

PhyloP100: 2.40

Publications

1 publications found
Variant links:
Genes affected
CEACAM16 (HGNC:31948): (CEA cell adhesion molecule 16, tectorial membrane component) The protein encoded by this gene is a secreted glycoprotein that in mouse interacts with tectorial membrane proteins in the inner ear. The encoded adhesion protein is found in cochlear outer hair cells and appears to be important for proper hearing over an extended frequency range. Defects in this gene likely are a cause of non-syndromic autosomal dominant hearing loss. [provided by RefSeq, May 2012]
CEACAM16-AS1 (HGNC:55317): (CEACAM16, CEACAM19 and PVR antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -4 ACMG points.

PP3
MetaRNN computational evidence supports a deleterious effect, 0.794
BP6
Variant 19-44703427-T-A is Benign according to our data. Variant chr19-44703427-T-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 504866.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00023 (35/152198) while in subpopulation AFR AF = 0.000772 (32/41452). AF 95% confidence interval is 0.000562. There are 0 homozygotes in GnomAd4. There are 20 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CEACAM16NM_001039213.4 linkc.116T>A p.Leu39Gln missense_variant Exon 3 of 7 ENST00000587331.7 NP_001034302.2 Q2WEN9
CEACAM16XM_017026795.2 linkc.116T>A p.Leu39Gln missense_variant Exon 2 of 5 XP_016882284.1
CEACAM16-AS1NR_186815.1 linkn.348-4250A>T intron_variant Intron 1 of 1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CEACAM16ENST00000587331.7 linkc.116T>A p.Leu39Gln missense_variant Exon 3 of 7 1 NM_001039213.4 ENSP00000466561.1 Q2WEN9

Frequencies

GnomAD3 genomes
AF:
0.000230
AC:
35
AN:
152198
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000772
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000196
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000724
AC:
18
AN:
248778
AF XY:
0.0000888
show subpopulations
Gnomad AFR exome
AF:
0.000906
Gnomad AMR exome
AF:
0.000116
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000294
AC:
43
AN:
1461514
Hom.:
0
Cov.:
32
AF XY:
0.0000275
AC XY:
20
AN XY:
727056
show subpopulations
African (AFR)
AF:
0.000926
AC:
31
AN:
33480
American (AMR)
AF:
0.0000894
AC:
4
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53216
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5764
European-Non Finnish (NFE)
AF:
8.99e-7
AC:
1
AN:
1111870
Other (OTH)
AF:
0.000116
AC:
7
AN:
60370
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
4
8
11
15
19
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000230
AC:
35
AN:
152198
Hom.:
0
Cov.:
32
AF XY:
0.000269
AC XY:
20
AN XY:
74360
show subpopulations
African (AFR)
AF:
0.000772
AC:
32
AN:
41452
American (AMR)
AF:
0.000196
AC:
3
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5202
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10616
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68026
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
2
4
6
8
10
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000712
Hom.:
0
Bravo
AF:
0.000344
ESP6500AA
AF:
0.000241
AC:
1
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.0000661
AC:
8

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Uncertain:1
Jan 30, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Leu39Gln variant in CEACAM16 has not been previously reported in individua ls with hearing loss, but has been identified in 0.08% (20/23988) of African chr omosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitut e.org/; dbSNP rs375722926). Although this variant has been seen in the general p opulation, its frequency is not high enough to rule out a pathogenic role. Compu tational prediction tools and conservation analysis do not provide strong suppor t for or against an impact to the protein. In summary, the clinical significanc e of the p.Leu39Gln variant is uncertain. ACMG/AMP criteria applied: None -

not provided Benign:1
Jul 31, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.88
BayesDel_addAF
Benign
-0.080
T
BayesDel_noAF
Uncertain
0.040
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.43
T;T
Eigen
Uncertain
0.51
Eigen_PC
Uncertain
0.36
FATHMM_MKL
Benign
0.75
D
LIST_S2
Benign
0.79
.;T
M_CAP
Benign
0.024
T
MetaRNN
Pathogenic
0.79
D;D
MetaSVM
Benign
-0.97
T
MutationAssessor
Pathogenic
3.4
M;M
PhyloP100
2.4
PrimateAI
Benign
0.47
T
PROVEAN
Pathogenic
-5.5
.;D
REVEL
Benign
0.28
Sift
Pathogenic
0.0
.;D
Sift4G
Pathogenic
0.0
D;D
Vest4
0.92
MVP
0.67
MPC
0.62
ClinPred
0.48
T
GERP RS
5.2
Varity_R
0.68
gMVP
0.88
Mutation Taster
=92/8
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs375722926; hg19: chr19-45206697; API